Table 1 Major clinical trials of CAR-T cell therapy for solid tumors
From: Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Type of cancer | Target | NCT | n | Year | Phase | Company | Status |
|---|---|---|---|---|---|---|---|
Lung cancer | EGFR | NCT05060796 | 11 | 2019 | I | *NR (sponsor: Second Affiliated Hospital of Guangzhou Medical University) | Recruiting |
NCT05060796 | 11 | 2019 | Early I | NR (sponsor: Second Affiliated Hospital of Guangzhou Medical University) | Recruiting | ||
HER2 | NCT03740256 | 45 | 2020 | I | NR (sponsor: Baylor College of Medicine) | Recruiting | |
NCT01935843 | 10 | 2013 | I/II | NR (sponsor: Chinese PLA General Hospital) | Unknown | ||
CEA | NCT02349724 | 75 | 2015 | I | NR (sponsor: Southwest Hospital, China) | Unknown | |
NCT04348643 | 40 | 2020 | I/II | Chongqing Precision Biotech Co., Ltd | Recruiting | ||
MSLN | NCT03054298 | 27 | 2017 | I | NR (sponsor: University of Pennsylvania) | Recruiting | |
NCT01583686 | 15 | 2012 | I/II | NR (sponsor: National Cancer Institute, NCI) | Terminated | ||
MUC1 | NCT02587689 | 60 | 2015 | I/II | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | |
NCT03525782 | 20 | 2018 | I/II | NR (sponsor: Hospital of Guangdong Pharmaceutical University) | Recruiting | ||
PD-L1 | NCT02862028 | 20 | 2016 | I/II | NR (sponsor: Shanghai International Medical Center) | Unknown | |
ROR1 | NCT02706392 | 60 | 2022 | I | NR (sponsor: Fred Hutchinson Cancer Center) | Recruiting | |
GPC3 or TGFβ | NCT03198546 | 30 | 2017 | I | NR (sponsor: Hospital of Guangzhou Medical University) | Recruiting | |
NY-ESO-1 or EGFR V III | NCT03638206 | 73 | 2018 | I/II | Shenzhen BinDeBio Ltd. | Recruiting | |
MAGE-A1, MAGE-A4, MucI, GD2, and MSLN | NCT03356808 | 20 | 2017 | I/II | Shenzhen Geno-Immune Medical Institute | Recruiting | |
HER2, MSLN, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3 | NCT04842812 | 40 | 2021 | I | NR (sponsor: Hospital of Guangzhou Medical University) | Recruiting | |
Breast cancer | HER2 | NCT04650451 | 220 | 2020 | I | Bellicum Pharmaceuticals | Recruiting |
NCT03740256 | 45 | 2018 | I | NR (sponsor: Baylor College of Medicine) | Recruiting | ||
NCT03696030 | 39 | 2018 | I | NR (sponsor: City of Hope Medical Center) | Recruiting | ||
ROR1 | NCT02706392 | 60 | 2016 | I | NR (sponsor: Fred Hutchinson Cancer Center) | Recruiting | |
c-MET | NCT01837602 | 6 | 2013 | I | NR (sponsor: University of Pennsylvania) | Completed | |
NCT03060356 | 77 | 2017 | I | NR (sponsor: University of Pennsylvania) | Terminated | ||
MSLN | NCT02792114 | 36 | 2016 | I | NR (sponsor: Memorial Sloan Kettering Cancer Center) | Recruiting | |
NCT02414269 | 179 | 2015 | I | NR (sponsor: Memorial Sloan Kettering Cancer Center) | Recruiting | ||
MUC1 | NCT02587689 | 20 | 2015 | I | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | |
CD44v6 | NCT04427449 | 100 | 2020 | I/II | Shenzhen Geno-Immune Medical Institute | Recruiting | |
EpCAM | NCT02915445 | 30 | 2016 | I | NR (sponsor: Sichuan University) | Recruiting | |
CD133 | NCT02541370 | 20 | 2015 | I | NR (sponsor: Chinese PLA General Hospital) | Completed | |
CD70 | NCT02830724 | 2 | 2016 | I/II | NR (sponsor: National Cancer Institute, NCI) | Suspension | |
CEA | NCT02349724 | 75 | 2015 | I | NR (sponsor: Southwest Hospital, China) | Unknown | |
NCT04348643 | 40 | 2020 | I/II | Chongqing Precision Biotech Co., Ltd | Recruiting | ||
NKG2D | NCT04107142 | 10 | 2019 | I | CytoMed Therapeutics Pte Ltd | Not yet recruiting | |
GD2 | NCT03635632 | 94 | 2018 | I | NR (sponsor: Baylor College of Medicine) | Recruiting | |
Gastric cancer | EpCAM | NCT03563326 | 40 | 2018 | I | NR (sponsor: Jian-Kun Hu, West China Hospital) | Unknown |
HER2 | NCT04650451 | 220 | 2020 | I | Bellicum Pharmaceuticals | Suspended | |
NCT03740256 | 45 | 2018 | I | NR (sponsor: Baylor College of Medicine) | Recruiting | ||
CEA | NCT04348643 | 40 | 2020 | I | Chongqing Precision Biotech Co., Ltd | Recruiting | |
Claudin18.2 | NCT04581473 | 192 | 2020 | I/II | CARsgen Therapeutics Co., Ltd. | Recruiting | |
NCT04404595 | 110 | 2020 | I/I | CARsgen Therapeutics Co., Ltd. | Recruiting | ||
MUC1 | NCT05239143 | 100 | 2022 | I | Poseida Therapeutics, Inc. | Recruiting | |
MSLN | NCT03941626 | 50 | 2019 | I/II | Shenzhen BinDeBio Ltd. | Unknown | |
B7H3 | NCT04864821 | 24 | 2021 | I | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | |
EGFR | NCT03740256 | 45 | 2018 | I | NR (sponsor: Baylor College of Medicine) | Recruiting | |
NKG2DL | NCT04550663 | 10 | 2020 | I | NR (sponsor: The Nanjing Drum Tower Hospital) | Unknown | |
Liver Cancer | GPC3 | NCT03198546 | 30 | 2017 | I | NR (sponsor: Hospital of Guangzhou Medical University) | Recruiting |
CEA | NCT02416466 | 8 | 2015 | I | NR (sponsor: Roger Williams Medical Center) | Completed | |
CD133 | NCT02541370 | 20 | 2015 | I/II | NR (sponsor: Chinese PLA General Hospital) | Completed | |
AFP | NCT03253289 | 13 | 2017 | I | NR (sponsor: Tannaz Armaghnay) | Active, not recruiting | |
EGFRvIII | NCT03941626 | 10 | 2019 | I | Shenzhen BinDeBio Ltd. | Active, not recruiting | |
B7H3 | NCT05323201 | 15 | 2022 | I/II | NR (sponsor: The Affiliated Hospital of Xuzhou Medical University) | Recruiting | |
EpCAM | NCT03013712 | 60 | 2017 | I/II | NR (sponsor: First Affiliated Hospital of Chengdu Medical College) | Unknown | |
MUC1 | NCT04842812 | 40 | 2021 | I | NR (sponsor: Hospital of Guangzhou Medical University) | Recruiting | |
NKG2DL | NCT04550663 | 10 | 2020 | I | NR (sponsor: Nanjing Drum Tower Hospital of Nanjing University Medical School) | Unknown | |
PD-L1 | NCT03672305 | 50 | 2018 | Early 1 | NR (sponsor: The Second Hospital of Nanjing Medical University) | Unknown | |
CD147 | NCT03993743 | 30 | 2019 | I | NR (sponsor: Xijing Hospital) | Unknown | |
Pancreatic cancer | MSLN | NCT02159716 | 19 | 2014 | I | NR (sponsor: University of Pennsylvania) | Completed |
| Â | NCT03198546 | 30 | 2017 | I | NR (sponsor: Hospital of Guangzhou Medical University) | Recruiting | |
EGFR | NCT01869166 | 60 | 2013 | I/II | NR (sponsor: Chinese PLA General Hospital) | Unknown | |
HER2 | NCT01935843 | 10 | 2013 | I/II | NR (sponsor: Chinese PLA General Hospital) | Unknown | |
CEA | NCT02850536 | 5 | 2016 | I | NR (sponsor: Roger Williams Medical Center) | Completed | |
CD133 | NCT02541370 | 20 | 2015 | I/II | NR (sponsor: Chinese PLA General Hospital) | Completed | |
B7H3 | NCT05143151 | 10 | 2021 | I/II | NR (sponsor: Shenzhen University General Hospital) | Recruiting | |
PSCA | NCT03267173 | 10 | 2017 | I | NR (sponsor: Hospital of Harbin Medical University) | Unknown | |
MUC1 | NCT05239143 | 100 | 2022 | I | Poseida Therapeutics, Inc. | Recruiting | |
EpCAM | NCT05028933 | 48 | 2021 | I | NR (sponsor: Zhejiang University) | Recruiting | |
ROBO1 | NCT03941457 | 9 | 2019 | I/II | Asclepius Technology Company Group (Suzhou) Co., Ltd. | Unknown | |
Colorectal cancer | CEA | NCT02349724 | 75 | 2015 | I | NR (sponsor: Southwest Hospital, China) | Unknown |
NCT02850536 | 5 | 2016 | I | NR (sponsor: Roger Williams Medical Center) | Completed | ||
NCT04348643 | 40 | 2020 | I/II | Chongqing Precision Biotech Co., Ltd | Recruiting | ||
NCT02959151 | 20 | 2016 | I/II | Shanghai GeneChem Co., Ltd. | Unknown | ||
MSLN | NCT05089266 | 30 | 2021 | I | Shanghai Cell Therapy Group Co.,Ltd | Not yet recruiting | |
NCT04503980 | 10 | 2020 | I | Shanghai Cell Therapy Group Co.,Ltd | Unknown | ||
EpCAM | NCT05028933 | 48 | 2021 | I | NR (sponsor: Zhejiang University) | Recruiting | |
MUC1 | NCT05239143 | 100 | 2022 | I | Poseida Therapeutics, Inc. | Recruiting | |
NCT02617134 | 20 | 2015 | I/II | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | ||
HER2 | NCT03740256 | 45 | 2018 | I | NR (sponsor: Baylor College of Medicine) | Recruiting | |
B7-H3 | NCT05190185 | 18 | 2022 | I | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Recruiting | |
EGFR | NCT03542799 | 20 | 2018 | I | NR (sponsor: Shenzhen Second People’s Hospital) | Unknown | |
NCT03152435 | 20 | 2017 | I/II | NR (sponsor: Shenzhen Second People’s Hospital) | Unknown | ||
CD133 | NCT02541370 | 20 | 2015 | I/II | NR (sponsor: Chinese PLA General Hospital) | Completed | |
c-Met | NCT03638206 | 73 | 2018 | I/II | Shenzhen BinDeBio Ltd. | Unknown | |
Esophageal cancer | HER2 | NCT03740256 | 45 | 2018 | I | NR (sponsor: Baylor College of Medicine) | Recruiting |
EpCAM | NCT03013712 | 60 | 2017 | I/II | NR (sponsor: Hospital of Chengdu Medical College) | Unknown | |
NY-ESO-1 | NCT03941626 | 50 | 2019 | I/II | Shenzhen BinDeBio Ltd. | Unknown | |
MUC1 | NCT03706326 | 20 | 2018 | I/II | NR (sponsor: Hospital of Guangdong Pharmaceutical University) | Unknown | |
Ovarian cancer | MSLN | NCT03615313 | 50 | 2018 | I/II | Shanghai Cell Therapy Research Institute | Unknown |
FRα | NCT03585764 | 18 | 2018 | I | NR (sponsor: University of Pennsylvania) | Recruiting | |
HER2 | NCT04660929 | 48 | 2020 | I | Carisma Therapeutics, Inc. | Recruiting | |
ALPPL2 | NCT04627740 | 20 | 2020 | I/II | NR (sponsor: Xinqiao Hospital of Chongqing) | Not yet recruiting | |
B7H3 | NCT04670068 | 21 | 2020 | I | NR (sponsor: UNC Lineberger Comprehensive Cancer Center) | Recruiting | |
TAG72 | NCT05225363 | 33 | 2022 | I | NR (sponsor: City of Hope Medical Center) | Recruiting | |
MUC1 | NCT05239143 | 100 | 2022 | I | Poseida Therapeutics, Inc. | Recruiting | |
CD70 | NCT02830724 | 124 | 2016 | I/II | NR (sponsor: National Cancer Institute, NCI) | Recruiting | |
Glioma | IL13Rα2 | NCT02208362 | 82 | 2014 | I | NR (sponsor: City of Hope Medical Center) | Active, not recruiting |
NCT00730613 | 3 | 2008 | I | NR (sponsor: City of Hope Medical Center) | Completed | ||
EGFRvIII | NCT02209376 | 11 | 2014 | I | NR (sponsor: University of Pennsylvania) | Terminated | |
HER2 | NCT03500991 | 48 | 2018 | I | NR (sponsor: Seattle Children’s Hospital) | Recruiting | |
EphA2 | NCT03423992 | 100 | 2018 | I | NR (sponsor: Xuanwu Hospital, Beijing) | Unknown | |
MUC1 | NCT02617134 | 20 | 2015 | I/II | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | |
CD147 | NCT04045847 | 31 | 2019 | Early I | NR (sponsor: Xijing Hospital) | Unknown | |
MMP2 | NCT04214392 | 36 | 2020 | I | NR (sponsor: City of Hope Medical Center) | Recruiting | |
Head and neck squamous cell carcinoma | HER2 | NCT03740256 | 45 | 2018 | I | NR (sponsor: Baylor College of Medicine) | Recruiting |
MUC1 | NCT05239143 | 100 | 2022 | I | Poseida Therapeutics, Inc. | Recruiting |